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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Factor V Leiden mutation, prothrombin gene mutation, and deficiencies
in coagulation inhibitors associated with Budd-Chiari syndrome
and portal vein thrombosis: results of a case-control study
Harry L. A. Janssen, Johan R. Meinardi, Frank P. Vleggaar, Stan H. M. van Uum, Elizabeth B. Haagsma, Felix J. M. van der Meer,
Jan van Hattum, Robert A. F. M. Chamuleau, Rob P. Adang, Jan P. Vandenbroucke, Bart van Hoek, and Frits R. Rosendaal
In a collaborative multicenter case-con-
trol study, we investigated the effect of
factor V Leiden mutation, prothrombin
gene mutation, and inherited deficiencies
of protein C, protein S, and antithrombin
on the risk of Budd-Chiari syndrome
(BCS) and portal vein thrombosis (PVT).
We compared 43 BCS patients and 92
PVT patients with 474 population-based
controls. The relative risk of BCS was
11.3 (95% CI 4.8-26.5) for individuals with
factor V Leiden mutation, 2.1(95% CI 0.4-
9.6) for those with prothrombin gene mu-
tation, and 6.8 (95% CI 1.9-24.4) for those
with protein C deficiency. The relative risk
of PVT was 2.7 (95% CI 1.1-6.9) for indi-
viduals with factor V Leiden mutation, 1.4
(95% CI 0.4-5.2) for those with prothrom-
bin gene mutation, and 4.6 (95% CI 1.5-
14.1) for those with protein C deficiency.
The relative risk of BCS or PVT was not
increased in the presence of inherited
protein S or antithrombin deficiency. Con-
currence of either acquired or inherited
thrombotic risk factors was observed in
26% of the BCS patients and 37% of the
PVT patients. We conclude that factor V
Leiden mutation and hereditary protein C
deficiency appear to be important risk
factors for BCS and PVT. Although the
prevalence of the prothrombin gene muta-
tion was increased, it was not found to be
a significant risk factor for BCS and PVT.
The coexistence of thrombogenic risk
factors in many patients indicates that
BCS and PVT can be the result of a
combined effect of different pathogenetic
mechanisms. (Blood. 2000;96:2364-2368)
© 2000 by The American Society of Hematology
Introduction
Budd-Chiari syndrome (BCS) represents occlusion of hepatic
outflow either at the level of the hepatic veins or inferior vena
cava.1 Clinically, the disease is characterized by hepatomegaly,
manifestations of portal hypertension, and sometimes rapidly
deteriorating liver function.2 Portal vein thrombosis (PVT) often
occurs in conditions leading to decreased portal flow and also
becomes manifest by symptoms of portal hypertension.3 Both BCS
and PVT have been linked to several hypercoagulable states,
primarily myeloproliferative disorders.4 However, most studies on
the pathogenesis of BCS and PVT contain few patients or are
hampered by the lack of complete testing for thrombophilia and
absence of a well-documented control group.
Resistance to activated protein C due to factor V Leiden mutation is
to date the most frequent cause of hereditary thrombophilia.5,6 Its
prevalence in the general white population is approximately 5%, but the
relative risk of BCS and PVT for subjects carrying factor V Leiden
mutation is uncertain. In a recent study, factor V Leiden appeared to be
present in about one fourth of patients with BCS, whereas its occurrence
in patients with PVT was negligible.7
Carriers of the prothrombin gene mutation, which results from
guanine to adenine transition at nucleotide position 20210 in the 39
untranslated region of the gene, exhibit increased plasma levels of
prothrombin and may therefore be at increased risk for venous
thromboembolisms.8 This mutation, also referred to as prothrombin
20210 A variant, has recently been recognized as a risk factor for a
selected group of patients with idiopathic PVT.9 With regard to
BCS, the impact of the prothrombin gene mutation is uncertain.10
For both BCS and PVT, the importance of several other hypercoag-
ulable states, such as inherited deficiencies of the coagulation
inhibitors protein C, protein S, and antithrombin, is also unknown
because their association with BCS and PVT is based solely on
anecdotal reports.11,12
We initiated a large multicenter population-based case-control
study to establish the influence of factor V Leiden mutation,
prothrombin gene mutation, protein C deficiency, protein S defi-
ciency, or antithrombin deficiency on the risk of BCS and PVT.
Patients and methods
Patients were selected by means of a search in the computerized
hospital registration systems (ZIS) of 7 academic hospitals in The
Netherlands. The hospitals were located in Leiden, Groningen,
Rotterdam, Utrecht, Nijmegen, Amsterdam, and Maastricht. All
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patients registered with the diagnosis of BCS or PVT between
January 1984 and July 1997 were identified. Diagnostic criteria for
BCS and PVT were partial or complete obstruction of hepatic
outflow or the portal vein, respectively, as documented by appropri-
ate radiographic abdominal imaging (ie, Doppler ultrasonography,
computed tomography, magnetic resonance imaging, venography)
or laparotomy. We excluded patients with veno-occlusive disease,
patients with hepatic outflow obstruction caused by congestive
heart failure, and patients who were younger than 15 years of age in
July 1997. For all identified patients (BCS, n 5 76; PVT, n 5 214)
a standardized questionnaire, asking for specific clinical informa-
tion to confirm the diagnosis of PVT and BCS, was completed with
data obtained from the medical charts by local investigators under
close supervision of one member of our team (H.L.A.J.). Twenty-
five patients with BCS and 100 with PVT had died before July
1997. Patients alive were asked to visit the hospital in which they
were registered for blood sampling, at the same time enabling
investigators to complete the questionnaire with information on
previous thrombotic events, familial thrombosis, acquired risk
factors of thrombosis, and the use of anticoagulants at the time of
venipuncture. Eight patients could not be traced, 14 were unwilling
to participate, and 5 were registered in 2 hospitals; in 3 cases
insufficient material for DNA extraction was obtained. Forty-three
patients with BCS and 92 patients with PVT were enrolled in the
study and underwent a full screening for thrombogenic disorders.
Five patients had both BCS and PVT. These patients were included
in the analyses of both diseases. The population-based control
group consisted of 474 healthy individuals who had no history of
venous thromboembolism, had not used coumarin derivatives for at
least 3 months before blood sampling, and had no myeloprolifera-
tive or malignant disease (LETS study control population6). Age,
sex, and ethnic descent of patients and the controls were similar.
More than 95% of patients and controls were of Caucasian origin.
The study was approved by the ethical committee of each
participating hospital and the participants gave their informed
consent before entering the study.
Blood was collected in tubes containing 3.2% trisodium citrate.
After centrifugation for 10 minutes at 2000g, plasma and white
blood cells were separated and stored at 220°C until analysis.
Material was collected and transported to Leiden by the study
coordinators. All laboratory assessments were performed at the
Haemostasis and Thrombosis Research Centre of the Academic
Hospital Leiden. High molecular weight DNA was isolated from
the white blood cell fraction by standard methods. The presence of
mutations in the factor V gene (1691, G3A) and the prothrombin
gene (20 210, G3A) was determined as previously described.5,8
Other coagulation assays were done according to established
procedures: protein C activity and antithrombin activity were
measured by Coamate (Chromogenix, Mo¨lndal, Sweden) on an
ACL-200 (Instrumentation Laboratory, Milan, Italy), total protein
S antigen by a polyclonal enzyme-linked immunosorbent assay,
factor II and factor X antigen by immunoelectrophoresis, and factor
V activity by a one-stage clotting assay on an Electra 1000C
coagulometer (MLA, Pleasantville, New York). In view of poten-
tial liver failure and anticoagulant treatment of patients with BCS
and PVT, the presence of hereditary deficiencies of protein C,
protein S, and antithrombin could only be estimated by modified
criteria as compared to controls. For controls the criteria for
diagnosis of protein deficiencies were plasma levels under the
lower limit of normal, combined with normal factor II and
prothrombin time values.13 Patients with BCS and PVT who
satisfied these protein deficiency criteria and those with a ratio of
protein C antigen, protein S antigen, or antithrombin value to
(factor II 1 factor X)/2 below 0.714 were selected for individual
evaluation of the presence of hereditary protein deficiencies by 2
hemostasis physicians (F.R.R. and F.J.M.v.d.M.). These investiga-
tors, who were not involved in patient management and were
unaware of the hepatologic diagnosis, based their decision on the
results of protein C, protein S, and antithrombin testing in relation
to the patient’s use of anticoagulants, the use of oral contraceptives,
and the degree of liver failure as indicated by results of a panel of
coagulation tests (protein C, protein S, antithrombin, fibrinogen,
prothrombin time, partial thromboplastin time, factor II, factor V,
and factor X). A clear isolated deficiency of either coagulation
inhibitor in comparison to other coagulation tests was considered
as an inherited deficiency. In all cases, the presence of myeloprolif-
erative disease was confirmed by bone marrow examination. Latent
primary myeloproliferative disorder, as diagnosed by erythroid
colony formation, was not tested in all patients and was not
considered to be a myeloproliferative disease. Six BCS patients and
4 PVT patients had undergone liver transplantation before the date
of blood sampling. For 7 of these 10 patients plasma taken before
liver transplantation could be obtained and investigated for protein
C, protein S, and antithrombin deficiency. Separate analysis of the
pretransplantation samples did not alter the decision on inherited
deficiency of these coagulation inhibitors. The frequencies of factor
V Leiden mutation, prothrombin mutation, and deficiency of
protein C, protein S, and antithrombin among cases and controls
were compared by simple cross-tabulation. Patients who, except
for these investigated inherited thrombogenic conditions, did not
exhibit risk factors for thrombosis were referred to as idiopathic
cases. The relative risks of BCS or PVT among individuals with
thrombogenic conditions were estimated as the odds ratio (OR) and
the 95% confidence interval (CI) according to Woolf.15
Results
Characteristics of patients and controls are shown in Table 1.
Myeloproliferative disease was present in 12 (28%) BCS patients
and 16 (17%) PVT patients. Thirty-two (74%) BCS patients and 24
(26%) PVT patients were treated with coumarin derivatives. This
difference may be attributable not only to the lack of evidence that
Table 1. Characteristics of patients with Budd-Chiari syndrome (BCS) and
portal vein thrombosis (PVT) and controls
BCS
n 5 43
PVT
n 5 92
Controls
n 5 474
Age* (y) 40 (19-60) 51 (19-83) 47 (16-73)
Male (%) 16 (37) 48 (52) 202 (43)
Oral anticoagulation (%) 32 (74) 24 (26) —
Duration of disease* (y) 6.4 (0.3-25) 7.0 (0.5-45) —
Myeloproliferative disorders (%) 12 (28) 16 (17) —
Polycythemia vera (%) 10 (23) 8 (9) —
Essential thrombocythemia (%) 1 (2) 3 (3) —
Myelofibrosis (%) — 4 (4) —
Unclassified (%) 1 (2) 1 (1) —
PNH (%) — 2 (2) —
Lupus anticoagulant (%) 2 (5) — —
Biopsy documented cirrhosis (%) 6 (14) 16 (17) —
History of pancreatitis (%) — 10 (11) —
Previous abdominal surgery (%) 10 (23) 28 (30) NA
Oral contraceptives (%) 12 (28) 12 (13) 65 (14)
PNH indicates paroxysmal nocturnal hemoglobinuria; NA, not available.
*Median (range).
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anticoagulation is beneficial in PVT but also to the predominance
of variceal bleeding in PVT patients (36%) compared to BCS
patients (7%).
Among the 43 BCS patients factor V Leiden mutation (n 5 11,
25.6%, OR 11.3, 95% CI 4.8-26.5), hereditary protein C deficiency
(n 5 4, 9.3%, OR 6.8, 95% CI 1.9-24.4) and prothrombin gene
mutation (n 5 2, 4.7%, OR 2.1, 95% CI 0.4-9.6) were more
prevalent than in controls (Table 2). In particular, factor V Leiden
mutation and protein C deficiency were predominant risk factors
for BCS. One patient exhibited homozygous carriership for factor
V Leiden mutation; the combined presence of factor V Leiden
mutation and hereditary protein C deficiency was found in 2
patients. Protein S deficiency and antithrombin deficiency could
not be demonstrated for any of the BCS patients. Among the 19
patients with idiopathic BCS, factor V Leiden mutation was found
in 7 (36.8%, OR 19.1, 95% CI 6.5-56.0) protein C deficiency in 2
(10.5%, OR 7.8, 95% CI 1.5-40.6), and prothrombin gene mutation
in none.
Among the 92 PVT patients, factor V Leiden mutation was
observed in 7 patients (7.6%, OR 2.7, 95% CI 1.1-6.9), hereditary
protein C deficiency in 6 patients (6.5%, OR 4.6, 95% CI 1.5-14.1),
and prothrombin gene mutation in 3 patients (3.2%, OR 1.4, 95%
CI 0.4-5.2) (Table 3). Although less pronounced than in the BCS
group, the relative risk of PVT was increased in the presence of
these thrombogenic factors. In one patient with primary biliary
cirrhosis factor V Leiden mutation and protein C deficiency were
present simultaneously. The prevalence of both protein S defi-
ciency (2.2%, OR 0.9, 95% CI 0.2-4.3) and antithrombin defi-
ciency (1.1%, OR 0.6, 95% CI 0.1-4.5) was low, being comparable
to that found for controls. In the group of 21 patients with
idiopathic PVT factor V Leiden mutation was observed in 3
(14.2%, OR 5.5, 95% CI 1.4-20.7), prothrombin gene mutation in 1
(4.8%, OR 2.1, 95% CI 0.3-17.1), and protein C deficiency in none.
Use of oral contraceptives was an important acquired risk factor
for BCS and PVT. Among women in the age group of 15 to 49
years, oral contraceptives had been used at the time of diagnosis in
12 of 20 patients (60.0%, OR 2.4, 95% CI 0.9-6.2) with BCS and in
12 of 25 patients (48.0%, OR 1.5, 95% C 0.6-3.4) with PVT
compared to 65 of 169 (38%) controls. Concurrence of inherited
thrombogenic factors (ie, factor V Leiden mutation, prothrombin
gene mutation, protein C deficiency, protein S deficiency, and
antithrombin deficiency) and acquired prothrombotic states for
BCS and PVT is shown in Table 4. For 11 of the 43 BCS patients
(26%) and 15 of the 92 PVT patients (16%) no risk factors for
thrombosis could be demonstrated. At least one of the inherited
prothrombotic risk factors was present in 14 patients with BCS
(32.5%, OR 3.9, 95% CI 1.9-7.9) and 17 patients with PVT (18.5%,
OR 1.8, 95% CI 1.0-3.3). Coexistence of acquired and inherited
risk factors was found for 6 (14%) of those with BCS and 13 (14%)
with PVT. Analysis of all thrombogenic risk factors, irrespective of
whether they were acquired or inherited, revealed 11 (26%)
patients with BCS and 34 (37%) patients with PVT who had more
than one risk factor (Table 5). Three BCS patients and 12 PVT
patients exhibited 3 or more factors considered to be a risk
for development of thrombosis in hepatic and portal veins,
respectively.
Discussion
This study shows a high prevalence of factor V Leiden mutation
and hereditary protein C deficiency in patients with BCS and PVT,
indicating that individuals with these thrombogenic conditions
have an increased relative risk for both manifestations of thrombo-
sis. The prevalence of the prothrombin gene mutation was less than
5% for BCS and PVT, and individuals with this mutation only had
an increased relative risk for BCS and PVT, which was not
significant. In general, the prevalence of the investigated hereditary
Table 2. Differences in prevalences of factor V Leiden mutation, prothrombin
gene mutation, protein C deficiency, protein S deficiency, and antithrombin
deficiency in patients with Budd-Chiari syndrome (BCS) and controls
BCS (%)
n 5 43
Controls (%)
n 5 474 OR 95% CI
Factor V Leiden mutation 11 (25.6) 14 (2.9) 11.3 4.8-26.5
Prothrombin gene mutation 2 (4.7) 11 (2.3) 2.1 0.4-9.6
Protein C deficiency 4 (9.3) 7 (1.5) 6.8 1.9-24.4
Protein S deficiency 0 (0) 11 (2.3) — —
Antithrombin deficiency 0 (0) 9 (1.9) — —
CI indicates confidence interval; OR, odds ratio.
Table 3. Differences in prevalences of factor V Leiden mutation, prothrombin
gene mutation, protein C deficiency, protein S deficiency, and antithrombin
deficiency in patients with portal vein thrombosis (PVT) and controls
PVT (%)
n 5 92
Controls (%)
n 5 474 OR 95% CI
Factor V Leiden mutation 7 (7.6) 14 (2.9) 2.7 1.1-6.9
Prothrombin gene mutation 3 (3.2) 11 (2.3) 1.4 0.4-5.2
Protein C deficiency 6 (6.5) 7 (1.5) 4.6 1.5-14.1
Protein S deficiency 2 (2.2) 11 (2.3) 0.9 0.2-4.3
Antithrombin deficiency 1 (1.1) 9 (1.9) 0.6 0.1-4.5
CI indicates confidence interval; OR, odds ratio.
Table 4. Prevalence of acquired and inherited risk factors for Budd-Chiari
syndrome (BCS) and portal vein thrombosis (PVT)
Acquired risk factor Inherited risk factor
BCS (%)
n 5 43
PVT (%)
n 5 92
2 2 11 (25.6) 15 (16.3)
1 2 18 (41.8) 60 (65.2)
2 1 8 (18.6) 4 (4.3)
1 1 6 (13.9) 13 (14.1)
BCS: Inherited risk factor: factor V Leiden mutation n 5 11, prothrombin gene
mutation n 5 2, protein C deficiency n 5 4. Acquired risk factor: oral contraceptives
n 5 12, myeloproliferative disease n 5 12, lupus anticoagulant n 5 2, inflammatory
bowel disease n 5 2, liver abscess n 5 1.
PVT: Inherited risk factor: factor V Leiden mutation n 5 7, prothrombin gene
mutation n 5 3, protein C deficiency n 5 6, protein S deficiency n 5 2, antithrombin
deficiency n 5 1. Acquired risk factor: oral contraceptives n 5 12, myeloproliferative
disease n 5 16, cirrhosis n 5 16, abdominal surgery n 5 28, pancreatitis n 5 10,
umbilical vein infection n 5 6, inflammatory bowel disease n 5 4, liver abscess n 5 4,
abdominal trauma n 5 2, paroxysmal nocturnal hemoglobinuria n 5 2, pregnancy n 5
2, nodular regenerative hyperplasia n 5 2, portal sclerosis n 5 1, hepatocellular
carcinoma n 5 1, seminoma n 5 1.
Table 5. Prevalence of combined risk factors (acquired and inherited) among
patients with Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT)
Number of risk factors*
BCS (%)
n 5 43
PVT (%)
n 5 92
0 11 (25.6) 15 (16.3)
1 21 (48.8) 43 (46.7)
2 8 (18.6) 22 (23.9)
3 3 (6.9) 9 (9.8)
4 — 3 (3.3)
. 4 — —
*Risk factors as shown.
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risk factors for thrombosis was especially high among patients with
idiopathic BCS and PVT.
Mahmoud and associates, who investigated 30 BCS patients
and 32 PVT patients, reported that factor V Leiden mutation was an
important factor in the pathogenesis of BCS but not of PVT.7 The
present study, which included 92 PVT patients and therefore had
more statistical power, demonstrates that factor V Leiden mutation
is also a risk factor for PVT. Chamouard and colleagues recently
found the prothrombin gene mutation in 4 of 10 patients with PVT.9
Although they investigated a subgroup of patients with idiopathic
PVT, the importance of the prothrombin gene mutation in the
etiology of PVT could well be overestimated in that study due to
the limited number of patients included. Large studies on venous
thromboembolisms did not show a mutation frequency of more
than 6.2%, and on pathophysiologic grounds there is no reason to
believe patients with the prothrombin gene mutation would exhibit
an additional risk for PVT.8
As previously documented for patients with deep venous
thrombosis,13 the prevalences of hereditary protein S deficiency
and antithrombin deficiency were low in both BCS and PVT
patients, and no differences with controls were observed. In view of
the low prevalences of these thrombogenic states as well as the
investigated diseases, we cannot exclude the association of protein
S or antithrombin deficiency with BCS and PVT, as was suggested
in several case reports.12,16,17 Although the higher prevalence of
protein S deficiency in our control group as compared to other
estimates would not suggest so, the use of total protein S values
instead of free protein S could have led to an underestimation of the
prevalence of inherited protein S deficiency in our study.13,18 In any
case, our results indicate that inherited defects of both protein S and
antithrombin are probably not major predisposing factors in the
pathogenesis of BCS and PVT.
At least one of the inherited prothrombotic risk factors investi-
gated (factor V Leiden mutation, prothrombin gene mutation, and
protein C, protein S, or antithrombin deficiency) was present in
approximately one third of the BCS population and in one fifth of
the PVT population. The fact that the significance of these
prothrombotic abnormalities was more pronounced in BCS than in
PVT can be explained by the heterogeneous etiology of PVT in
which many focal factors, such as abdominal surgery, pancreatitis,
and preexistent cirrhosis, appear to be of importance.
The diagnosis of inherited deficiencies in protein C, protein S,
and antithrombin in patients with BCS and PVT is difficult and
should be interpreted as estimates primarily because acquired
deficiencies can develop in the event of liver failure, acute
thrombosis, and anticoagulant therapy. To minimize the number of
incorrectly diagnosed inherited deficiencies we decided to (1)
evaluate the levels of protein C, protein S, and antithrombin in
relation to the levels of factor II and factor X, which are also liver-
and vitamin K-dependent factors, and (2) subject all patients with
an imbalance of these factors to review by a blinded expert panel.
Furthermore, as in many previous studies of BCS and PVT
patients, one might question whether selection is introduced by the
inclusion of only patients who were alive. Patients with fulminant
disease who died early in the course of their illness could bias the
results. Nevertheless, a bias would only be present if one assumes
that the investigated thrombogenic risk factors are directly related
to mortality in BCS and PVT. This is unlikely, but has never been
well investigated. For the present study, separate analysis of
thrombophilia screening, as performed by local hematologists,
indicated that 76% of the 25 registered patients with fatal BCS did
not reveal a major difference in the prevalence of the investigated
thrombogenic states. Most of the PVT patients who died were
incompletely tested for thrombophilia because they either had
abdominal malignancies or end-stage liver failure.
A remarkable finding of the present study is the coexistence of
several thrombophilic states in about one fourth of patients with
BCS and more than one third of those with PVT (Table 5). Several
patients even had 4 thrombotic risk factors of either acquired or
inherited origin. It is plausible that prothrombotic mutations in one
or more genes create an inherited predisposition for BCS and PVT.
Subsequent clinical thrombosis might then manifest in the presence
of thrombotic stimuli such as use of oral contraceptives, pregnancy,
myeloproliferative disease, and abdominal surgery.19 Hence, for
appropriate risk assessment even in the presence of an overt
thrombotic risk factor, physicians should request complete throm-
bophilia screening for patients with life-threatening thrombotic
manifestations such as BCS and PVT. With the continuing search
for genetic molecular defects, the number of thrombogenic disor-
ders will probably grow and we therefore might enter an era in
which true idiopathic thrombotic disease will become uncommon.
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